Momenta Pharmaceuticals, Inc.
MNTA
MNTA was delisted on the 30th of September, 2020.
162 hedge funds and large institutions have $873M invested in Momenta Pharmaceuticals, Inc. in 2017 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 64 increasing their positions, 49 reducing their positions, and 18 closing their positions.
368% more call options, than puts
Call options by funds: $1.54M | Put options by funds: $329K
39% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 18
31% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 49
1% more funds holding
Funds holding: 160 → 162 (+2)
9% less capital invested
Capital invested by funds: $962M → $873M (-$89.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$137M |
| 2 |
NI
Numeric Investors
Boston,
Massachusetts
|
+$14.4M |
| 3 |
State Street
Boston,
Massachusetts
|
+$9.05M |
| 4 |
FCMI
Foresite Capital Management III
Larkspur,
California
|
+$6.74M |
| 5 |
EDRH
Edmond de Rothschild Holding
Chambesy,
Switzerland
|
+$6.58M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Discovery Capital Management
South Norwalk,
Connecticut
|
-$22.7M |
| 2 |
Millennium Management
New York
|
-$17.6M |
| 3 |
O
OrbiMed
New York
|
-$13.2M |
| 4 |
SC
Samlyn Capital
New York
|
-$3.97M |
| 5 |
SAM
Senzar Asset Management
New York
|
-$3.42M |
MNTA Hedge Fund Activity: Q1 2017 in Review
162 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Momenta Pharmaceuticals, Inc. (MNTA) for Q1 2017, worth a combined $873M — down 9.3% from $962M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new MNTA positions and 18 closed out — a net gain of 7 holders — while 64 added to existing stakes and 49 trimmed.
The largest buyer was BlackRock, adding an estimated $137M. The largest seller was Discovery Capital Management, cutting an estimated $22.7M.
- 162 institutional investors held Momenta Pharmaceuticals, Inc. (MNTA) as of Q1 2017, up from 160 in Q4 2016.
- Funds reported $873M of Momenta Pharmaceuticals, Inc. stock for Q1 2017, down 9.3% quarter-over-quarter.
- 25 funds opened new Momenta Pharmaceuticals, Inc. positions in Q1 2017 and 18 closed out, a net change of +7 holders.
- The largest Momenta Pharmaceuticals, Inc. buyer in Q1 2017 was BlackRock, an estimated $137M added.
- The largest Momenta Pharmaceuticals, Inc. seller in Q1 2017 was Discovery Capital Management, an estimated $22.7M sold.
Based on aggregated 13F filings for Q1 2017.